Literature DB >> 17515544

Individual dopaminergic neurons show raised iron levels in Parkinson disease.

A E Oakley1, J F Collingwood, J Dobson, G Love, H R Perrott, J A Edwardson, M Elstner, C M Morris.   

Abstract

OBJECTIVE: Evidence suggests that abnormal iron metabolism is associated with Parkinson disease (PD), with raised iron levels found in pathologically affected areas in PD. It is unknown if this elevated iron is actually associated with neurons or reactive glia, and we therefore addressed this issue by determining if raised iron was present in single dopaminergic neurons.
METHODS: We used unfixed frozen sections from postmortem tissue of PD patients and elderly normal individuals to avoid metal contamination and translocation. Levels of iron and other elements were measured using sensitive and specific wavelength dispersive electron probe x-ray microanalysis coupled with cathodoluminescence spectroscopy in individual substantia nigra dopaminergic neurons.
RESULTS: We identified raised intraneuronal iron in single defined substantia nigra neurons in PD (mean neuronal iron 2,838 vs 1,611, p < 0.0001) but not in other movement disorders such as Huntington disease. These findings were unrelated to the density of remaining neurons.
CONCLUSIONS: Primary changes in neuronal iron could lead to neurodegeneration in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515544     DOI: 10.1212/01.wnl.0000262033.01945.9a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  93 in total

1.  Biomarkers: casting the net wide.

Authors:  Rachel Jones
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

2.  Unraveling the role of metal ions and low catalytic activity of cytochrome C oxidase in Alzheimer's disease.

Authors:  Trevor Alleyne; Neetu Mohan; Jerome Joseph; Andrew Adogwa
Journal:  J Mol Neurosci       Date:  2010-08-20       Impact factor: 3.444

3.  Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells.

Authors:  Wen-Jing Li; Hong Jiang; Ning Song; Jun-Xia Xie
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 4.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

Authors:  Peng Lei; Scott Ayton; David I Finkelstein; Loredana Spoerri; Giuseppe D Ciccotosto; David K Wright; Bruce X W Wong; Paul A Adlard; Robert A Cherny; Linh Q Lam; Blaine R Roberts; Irene Volitakis; Gary F Egan; Catriona A McLean; Roberto Cappai; James A Duce; Ashley I Bush
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

6.  Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Authors:  Shannon L Rhodes; Daniel D Buchanan; Ismaïl Ahmed; Kent D Taylor; Marie-Anne Loriot; Janet S Sinsheimer; Jeff M Bronstein; Alexis Elbaz; George D Mellick; Jerome I Rotter; Beate Ritz
Journal:  Neurobiol Dis       Date:  2013-10-08       Impact factor: 5.996

Review 7.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

Authors:  Jack T Rogers; Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Deborah H Smith; Xudong Huang; Sanghamitra Bandyopadhyay; Catherine M Cahill; Maria L Maccecchini; Debomoy K Lahiri; Nigel H Greig
Journal:  J Neural Transm (Vienna)       Date:  2011-01-08       Impact factor: 3.575

Review 9.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 10.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.

Authors:  David N Hauser; Teresa G Hastings
Journal:  Neurobiol Dis       Date:  2012-10-12       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.